Structure Therapeutics Inc ADR Stock Price, News & Analysis

Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic diseases, has announced its participation in two major healthcare investor conferences in June 2025:

• The Jefferies Global Healthcare Conference on June 5 at 8:10 a.m. ET in New York, featuring a fireside chat and one-on-one meetings
• The Goldman Sachs Global Healthcare Conference on June 11 at 10:40 a.m. ET in Miami, also including a fireside chat and one-on-one meetings

Both fireside chat sessions will be available via webcast on the company's investor relations website, with replays accessible for 90 days.

Structure Therapeutics (NASDAQ: GPCR) reported Q1 2025 financial results and milestones. The company's key oral obesity drug aleniglipron has two fully enrolled Phase 2b studies (ACCESS and ACCESS II) with topline data expected by end-2025. ACCESS enrolled 220 adults and evaluates doses up to 120mg, while ACCESS II enrolled 80 adults testing higher doses of 180mg and 240mg. Structure plans to initiate Phase 1 trials for ACCG-2671, their oral amylin receptor agonist, by year-end 2025. Financially, the company reported $836.9M in cash and investments, expected to fund operations through 2027. Q1 2025 showed increased R&D expenses of $42.9M (vs $20.7M in Q1 2024) and G&A expenses of $13.4M (vs $11.3M in Q1 2024), with a net loss of $46.8M.

Structure Therapeutics (NASDAQ: GPCR) announced completion of enrollment for its aleniglipron obesity treatment studies ACCESS and ACCESS II, with topline data expected by year-end 2025. The studies, involving over 300 patients, will evaluate doses up to 240mg with optimized titration regiments.

The company reported strong financials with $883.5 million in cash and investments, expected to fund operations through 2027. R&D expenses increased to $108.8 million for 2024, up from $70.1 million in 2023. Net loss for 2024 was $122.5 million.

Structure Therapeutics is advancing its oral small molecule obesity portfolio, including ACCG-2671, an oral amylin receptor agonist expected to begin Phase 1 trials by year-end 2025. The company also maintains pipeline programs targeting GIPR, GCGR, and APJR for obesity treatment.

Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic diseases, has announced its participation in three upcoming healthcare investor conferences.

The company will attend the Guggenheim SMID Cap Biotech Conference on February 5 in New York, featuring a fireside chat at 10:30 a.m. ET, the Leerink Global Healthcare Conference on March 10 in Miami with a fireside chat at 1:00 p.m. ET, and the Jefferies Biotech on the Bay Summit on March 11 in Miami for one-on-one meetings.

Webcasts of the fireside chats will be available on the company's investor relations website, with replays accessible for 90 days following the events.

Structure Therapeutics (NASDAQ: GPCR) has announced ACCG-2671 as its lead oral small molecule amylin receptor agonist for obesity treatment. The drug, designed as an oral Dual Amylin and Calcitonin Receptor Agonist (DACRA), is expected to enter Phase 1 clinical trials by year-end 2025.

Preclinical studies showed ACCG-2671 demonstrates potent target engagement, robust weight loss, and favorable safety profile supporting once-daily dosing. The company positions it as the most advanced oral small molecule amylin-based drug candidate, complementing their GLP-1 oral molecule GSBR-1290, with both intended for use as monotherapies and in fixed-dose combinations.

The drug showed cagrilintide-like efficacy in preclinical data with an oral small molecule profile, targeting amylin, a hormone that regulates glycemia and energy balance.

Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced its participation in the Jefferies London Healthcare Conference. The event will take place from November 19-21, 2024, in London, UK.

The company's management will deliver a presentation and participate in a fireside chat on Wednesday, November 20 at 8:00 a.m. GMT, while also hosting one-on-one meetings. A live webcast will be available on the company's website, with a replay accessible for 90 days following the event.

Structure Therapeutics (NASDAQ: GPCR) reported Q3 2024 financial results and recent milestones. The company has initiated Phase 2b ACCESS study of GSBR-1290 for obesity treatment, with topline data expected in Q4 2025. The company maintains a strong financial position with $915.3 million in cash and investments, expected to fund operations through 2027. Q3 2024 financial results show R&D expenses of $32.6 million (up from $17.5M in Q3 2023), G&A expenses of $13.2 million (up from $8.6M), and a net loss of $34.0 million. The company plans to select an oral small molecule amylin receptor agonist development candidate by end of 2024.

Structure Therapeutics has initiated dosing in its Phase 2b ACCESS clinical study for GSBR-1290, an oral small molecule GLP-1 receptor agonist for obesity treatment. The study will evaluate multiple doses up to 120 mg over 36 weeks in approximately 220 participants. Additionally, the company announced the Phase 2 ACCESS II study, which will test higher doses (180 and 240 mg) in about 82 participants. Both studies employ a "low and slow" titration approach, with topline data expected in Q4 2025. GSBR-1290 has shown competitive weight loss results and favorable safety in previous studies with once-daily dosing.

Structure Therapeutics (NASDAQ: GPCR) has announced multiple poster presentations at ObesityWeek® 2024, scheduled for November 3-6, 2024 in San Antonio, TX. The company will present three posters focusing on obesity treatment innovations:

1. A presentation on novel oral small molecule dual amylin and calcitonin receptor agonists for obesity treatment

2. Research on drug design principles and PK/PD of GSBR-1290, a small molecule GLP-1RA

3. Clinical results showing significant weight changes at 12 weeks with GSBR-1290

All presentations will take place in Exhibit Hall 4, with specific sessions scheduled for November 3-4.